...
首页> 外文期刊>Medical science monitor : >Diabetes mellitus: Complications and therapeutics.
【24h】

Diabetes mellitus: Complications and therapeutics.

机译:糖尿病:并发症和治疗方法。

获取原文

摘要

Diabetes mellitus has now assumed epidemic proportions in many countriesof the world. With the present population of 19.4 million diabetics, and approximately 60 million bythe year 2025, India would rank first in its share of the global burden of diabetes. Diabetes mellitusis characterized by derangement in carbohydrate, protein, and fat metabolism caused by complete or relativeinsufficiency of insulin secretion and/or insulin action. There are two main forms of diabetes, type1 (insulin-dependent diabetes mellitus) and type 2 (non-insulin-dependent diabetes mellitus). Insulinsensitizers (thiazolidinediones), new-generation insulin secretagogue (glimepiride), acarbose, and designerinsulin (lispro and aspart) have enormously helped in achieving better metabolic control. Despite thegreat strides that have been made in the understanding and management of type 2 diabetes, insulin resistanceand diabetes-related complications are increasing unabated. The present review not only updates our knowledgein delineating the molecular mechanism(s) causal to insulin sensitivity or resistance, but also providesclues for the prognosis of diabetes and its better management.
机译:现在,在世界许多国家中,糖尿病已呈流行趋势。目前,印度人口为1,940万,到2025年将达到约6,000万,印度将在全球糖尿病负担中位居第一。糖尿病的特征是由于胰岛素分泌和/或胰岛素作用的完全或相对不足引起碳水化合物,蛋白质和脂肪代谢紊乱。糖尿病有两种主要形式:1型(胰岛素依赖型糖尿病)和2型(非胰岛素依赖型糖尿病)。胰岛素增敏剂(噻唑烷二酮),新一代胰岛素促分泌剂(格列美脲),阿卡波糖和设计师胰岛素(赖脯和阿斯巴特)对实现更好的代谢控制有极大帮助。尽管在理解和控制2型糖尿病方面已取得了长足的进步,但胰岛素抵抗和与糖尿病相关的并发症正在不断增加。本综述不仅更新了我们描述胰岛素敏感性或抗药性的分子机制的知识,而且为糖尿病的预后及其更好的治疗提供了线索。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号